Breast Cancer

Investigators conclude that minimal residual disease cells, or those that survive the initial treatment, may carry some form of epigenetic and metabolic memory of the tumor.

After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.

There is a survival advantage for those who were also treated with surgery, according to new study results.

They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.

Patients receiving sacituzumab govitecan also reported lower symptomatic impact of fatigue, pain, dyspnea, and insomnia.

Allostatic load is caused by a number of different stressors, including social isolation, poverty, and racism, many of which are commonly experienced by individuals belonging to racial and ethnic minorities, according to the investigators.

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.

The investigators said these results suggest patients with low sTK1 activity levels have slow-growing disease, which can be initially controlled through single-drug endocrine therapy.

Margetuximab (Margenza) is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer.

Ribociclib is an inhibitor of cyclin-dependent kinase 4 and 6 and causes tumor growth inhibition.

In a phase 3 trial, the medication significantly reduced the risk of disease progression compared with individuals in a placebo group.

Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.

The results of a 5-year follow-up study comparing trastuzumab (Ontruzant) and reference medicine trastuzumab show comparable cardiac safety profiles and long-term efficacy.

Study suggests potentially expanding the use of immunotherapies in the elderly, a population in whom these therapies may be under-prescribed.

This drug class works by interfering with the ability of cancer cells to repair themselves after experiencing damage to their DNA, but how PARP inhibitors selectively kill cancer cells was previously unknown.

Atezolizumab was granted accelerated approval for the mTNBC indication in March 2019, making it the first immunotherapy agent to be approved in this setting.

This research lays the foundation for future clinical trials aimed at investigating whether moderate to vigorous exercise can minimize “chemo brain,” which is a decline in cognitive function many patients with breast cancer experience.

As health care costs rise and cost-sharing increases, treatment-associated expenses will continue to burden patients.

These findings could lead to improved therapies and prolonged survival for patients with metastatic TNBC, according to the study authors.

Investigators estimated that globally, 4.1% of all new cancer diagnoses in 2020 were attributable to alcohol consumption.

A decrease in cancer-associated macrophage-like cells was associated with an approximately 300% increase in mean progression-free survival.

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in OS for patients whose tumors expressed PD-L1 with a combined positive score ≥10 compared to chemotherapy alone, according to the study.

The combination of pembrolizumab and chemotherapy marks the first immunotherapy regimen approved for patients with high-risk early-stage triple-negative breast cancer.

The FDA has granted Fast Track Designation to trilaciclib (Cosela) for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC).

Margetuximab-cmkb (Margenza) was approved in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which for metastatic disease.